Furthermore, pharmacological inhibition of OS via the NOX inhibitor apocynin (Apo) downregulates AR expression, thereby ameliorating BPH through the AR/TGF-β/NOX4 signaling axis. This evidence concerns the gene NOX4 and benign prostatic hyperplasia.